当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Inducing Hypermutability to Promote Anti–PD-1 Therapy Response
Cancer Discovery ( IF 29.7 ) Pub Date : 2022-07-06 , DOI: 10.1158/2159-8290.cd-22-0492
Jason A Willis 1, 2 , Michael J Overman 1
Affiliation  

Summary: The lack of clinical activity from various immune-checkpoint blockade approaches in mismatch repair– proficient (MMRp) colorectal cancer has demonstrated a critical need for novel approaches. In this issue, Crisafulli and colleagues provide proof of concept for the induction of hypermutability through the use of temozolomide as a potential pathway for enabling a productive anti–PD-1 immune response in MMRp colorectal cancer. See related article by Crisafulli et al., p. 1656 (1) .

中文翻译:

诱导超突变以促进抗 PD-1 治疗反应

摘要:各种免疫检查点阻断方法在错配修复(MMRp)结肠直肠癌中缺乏临床活性,这表明迫切需要新的方法。在本期中,Crisafulli 及其同事通过使用替莫唑胺作为在 MMRp 结直肠癌中实现有效的抗 PD-1 免疫反应的潜在途径,提供了诱导超突变性的概念证明。请参阅 Crisafulli 等人的相关文章,第 17 页。1656(1)。
更新日期:2022-07-06
down
wechat
bug